Answers are grounded in this paper and cite their sources.
Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.
No takes yet. Share an insight, caveat, or question.
Frerichs et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: